Drug Profile
CLXMET 101
Alternative Names: CLX-MET-101; MSTM-101; MSTM-102Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Cellix Bio
- Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Drug conjugates; Hepatoprotectants
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in India (PO)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in India (PO)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in India (PO)